HK1026698A1 - Salt of naphthyridine carboxylic acid derivative - Google Patents

Salt of naphthyridine carboxylic acid derivative

Info

Publication number
HK1026698A1
HK1026698A1 HK00105435A HK00105435A HK1026698A1 HK 1026698 A1 HK1026698 A1 HK 1026698A1 HK 00105435 A HK00105435 A HK 00105435A HK 00105435 A HK00105435 A HK 00105435A HK 1026698 A1 HK1026698 A1 HK 1026698A1
Authority
HK
Hong Kong
Prior art keywords
carboxylic acid
salt
acid derivative
naphthyridine carboxylic
naphthyridine
Prior art date
Application number
HK00105435A
Other languages
English (en)
Inventor
Ae Ri Kim
Jin Hwa Lee
Ki Sook Park
Jong Ryoo Choi
Tae Hee Lee
Jay Hyok Chang
Do Hyun Nam
Hoon Choi
Original Assignee
Lg Chemical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lg Chemical Ltd filed Critical Lg Chemical Ltd
Publication of HK1026698A1 publication Critical patent/HK1026698A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/16Central respiratory analeptics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01Sulfonic acids
    • C07C309/02Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK00105435A 1997-03-21 2000-08-30 Salt of naphthyridine carboxylic acid derivative HK1026698A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR19970009840 1997-03-21
PCT/KR1998/000051 WO1998042705A1 (en) 1997-03-21 1998-03-20 Salt of naphthyridine carboxylic acid derivative

Publications (1)

Publication Number Publication Date
HK1026698A1 true HK1026698A1 (en) 2000-12-22

Family

ID=19500439

Family Applications (1)

Application Number Title Priority Date Filing Date
HK00105435A HK1026698A1 (en) 1997-03-21 2000-08-30 Salt of naphthyridine carboxylic acid derivative

Country Status (39)

Country Link
US (9) US7700617B2 (ja)
EP (2) EP1179533B1 (ja)
JP (3) JP3759962B2 (ja)
KR (1) KR100266499B1 (ja)
CN (1) CN1131229C (ja)
AP (1) AP1331A (ja)
AR (1) AR012125A1 (ja)
AT (2) ATE257836T1 (ja)
AU (1) AU726634B2 (ja)
BG (1) BG63972B1 (ja)
BR (1) BR9808290A (ja)
CA (1) CA2283671C (ja)
CZ (2) CZ288673B6 (ja)
DE (2) DE69814378T2 (ja)
DK (2) DK1179533T3 (ja)
DZ (1) DZ2448A1 (ja)
EA (1) EA001674B1 (ja)
ES (2) ES2198697T3 (ja)
HK (1) HK1026698A1 (ja)
HU (2) HU225412B1 (ja)
ID (1) ID22681A (ja)
IL (2) IL131812A0 (ja)
IN (1) IN188178B (ja)
IS (2) IS2093B (ja)
MA (1) MA24500A1 (ja)
MY (1) MY137653A (ja)
NO (1) NO312515B1 (ja)
NZ (1) NZ337748A (ja)
OA (1) OA11161A (ja)
PE (1) PE67999A1 (ja)
PL (1) PL191815B1 (ja)
PT (2) PT981527E (ja)
SA (1) SA98181055B1 (ja)
SI (2) SI1179533T1 (ja)
SK (1) SK284107B6 (ja)
TR (1) TR199902313T2 (ja)
UA (1) UA56218C2 (ja)
WO (1) WO1998042705A1 (ja)
ZA (1) ZA982335B (ja)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9820405D0 (en) 1998-09-18 1998-11-11 Smithkline Beecham Plc Process
SK13342001A3 (sk) * 1999-03-19 2002-04-04 Knoll Gmbh Použitie zlúčeniny a farmaceutická kompozícia ju obsahujúca
US6331550B1 (en) 1999-06-29 2001-12-18 Smithkline Beecham Corporation Methods of use of quinolone compounds against anaerobic pathogenic bacteria
US6262071B1 (en) 1999-06-29 2001-07-17 Smithkline Beecham Corporation Methods of use of antimicrobial compounds against pathogenic amycoplasma bacteria
US6803376B1 (en) 1999-06-29 2004-10-12 Smithkline Beecham Corporation Method of use of quinolone compounds against pneumococcal and haemophilus bacteria
CA2282066C (en) 1999-06-29 2010-09-07 Smithkline Beecham Corporation Methods of use of quinolone compounds against atypical upper respiratory pathogenic bacteria
GB9920919D0 (en) 1999-09-03 1999-11-10 Sb Pharmco Inc Novel compound
GB9920917D0 (en) * 1999-09-03 1999-11-10 Sb Pharmco Inc Novel process
JP2001097864A (ja) * 1999-09-24 2001-04-10 Smithkline Beecham Corp 呼吸管および尿路病原性細菌に対するフルオロキノリン化合物の使用方法
JP2001097863A (ja) * 1999-09-24 2001-04-10 Smithkline Beecham Corp 嫌気性病原菌に対するフルオロキノロン化合物の使用法
EP1561465A3 (en) * 1999-09-22 2005-12-21 LG Life Sciences, Ltd. Methods of use of fluoroquinolone compounds against bacteria
GR1003520B (el) * 1999-09-22 2001-01-22 Smithkline Beecham Plc Μεθοδος χρησης ενωσεων φλουοροκινολονης εναντια σε νοσοκομειακα αρνητικα κατα gramμ παθογενων βακτηριδιων
JP2001097891A (ja) * 1999-09-24 2001-04-10 Smithkline Beecham Corp 呼吸器系病原菌に対するフルオロキノロン化合物の使用法
GR1003521B (el) * 1999-09-23 2001-01-22 Smithkline Beecham Plc Μεθοδοι χρησεως ενωσεων φλουοροκινολονης εναντια κατα gram θετικων παθογονων βακτηριδιων
KR20010091379A (ko) * 2000-03-15 2001-10-23 성재갑 7-(4-아미노메틸-3-옥심)피롤리딘 치환체를 갖는 퀴놀린카르복실산 유도체의 신규 제조방법
SI1412078T1 (sl) 2001-08-02 2009-04-30 Lg Life Sciences Ltd Lg Twin T Postopki za pripravo amino-zaščitenih derivatov 4-aminometilen-pirolidin-3-ona, gemifloksacina ali njegove soli
MXPA04005179A (es) * 2001-11-30 2004-08-11 Lg Life Sciences Ltd Un metodo para tratar infecciones bacterianas usando gemifloxacina o una sal de la misma y una antibiotico de (-lactama.
KR100517638B1 (ko) * 2002-04-08 2005-09-28 주식회사 엘지생명과학 게미플록사신 산염의 새로운 제조방법
AR043880A1 (es) * 2003-04-22 2005-08-17 Solvay Pharm Gmbh Mesilato acido de 4-(4.trans-hidroxiciclohexil) amino-2-fenil-7h-pirrolo (2,3-d) pirimidina y sus formas polimorfas
US7834027B2 (en) 2005-06-15 2010-11-16 Hetero Drugs Limited Gemifloxacin process and polymorphs
KR101364900B1 (ko) * 2006-03-07 2014-02-19 욱크하트 리미티드 벤조퀴놀리진-2-카르복실산의 프로드러그
WO2010001408A2 (en) * 2008-06-06 2010-01-07 Matrix Laboratories Ltd. Novel polymorphic forms of gemifloxacin mesylate
WO2010146594A1 (en) * 2009-06-16 2010-12-23 Hetero Research Foundation Novel polymorphs of gemifloxacin mesylate
EP2491921A1 (en) * 2011-02-25 2012-08-29 Deva Holding Anonim Sirketi Conservation of anhydrous form of gemifloxacin
EP3254681B1 (en) * 2012-02-27 2019-06-19 Bristol-Myers Squibb Company N-(5s,6s,9r)-5-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5h-cyclohepta[b]pyridin-9-yl-4-(2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate salt
CZ2016104A3 (cs) * 2016-02-24 2017-09-06 Zentiva, K.S. Krystalické modifikace solí methyl (3Z)-3-{[(4-{methyl[(4-methylpiperazin-1-yl)acetyl]amino}fenyl)amino](fenyl)methyliden}-2-oxo-2,3-dihydro-1H-indol-6-karboxylátu a způsoby jejich přípravy

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR223983A1 (es) 1978-08-25 1981-10-15 Dainippon Pharmaceutical Co Un procedimiento para-preparar derivados de acido 6-halogeno-4-oxo-7-(1-piperazinil)-1,8-naftiridin-3-carboxilico
ES512969A0 (es) 1981-06-11 1983-02-16 Warner Lambert Co "un procedimiento para preparar sales de compuestos de naftiridina y quinoleina".
IN162769B (ja) 1984-11-13 1988-07-09 Kyorin Seiyaku Kk
NZ222047A (en) 1986-10-08 1991-01-29 Bristol Myers Co Quinoline - or naphthyridine - carboxylic acid anti-bacterial agents
JPH01100165A (ja) 1987-10-13 1989-04-18 Shionogi & Co Ltd オキシムまたはヒドロキシアミン誘導体系抗菌剤
US4920120A (en) 1988-01-25 1990-04-24 Warner-Lambert Company Antibacterial agents
US4931446A (en) * 1988-03-23 1990-06-05 Abbott Laboratories Antimicrobial for in-vitro diagnostic kits
CA1336090C (en) * 1988-08-31 1995-06-27 Isao Hayakawa Spiro-substituted cyclic amines of quinolone derivatives
US5286723A (en) * 1988-08-31 1994-02-15 Daiichi Seiyaku Co., Ltd. Spiro compound
PL166381B1 (pl) 1989-08-16 1995-05-31 Pfizer Sposób wytwarzania nowych podstawionych kwasów 7-azabicyklochinolonokarboksylowych PL PL PL PL
US5276041A (en) 1991-11-08 1994-01-04 Kaken Pharmaceutical Co., Ltd. Oxime derivatives
WO1993025545A1 (en) 1992-06-09 1993-12-23 Korea Research Institute Of Chemical Technology Novel quinoline derivatives and processes for preparing the same
DE69509442T2 (de) * 1994-06-16 1999-09-02 Lg Chemical Ltd Chinolincarbonsäurederivate mit 7-(4-Amino-methyl-3-oxim)-pyrrolidin-Substituenten und Verfahren zu ihrer Herstellung
US5776944A (en) * 1994-06-16 1998-07-07 Lg Chemical Ltd. 7-(4-aminomethyl-3-methyloxyiminopyrroplidin-1-yl)-1-cyclopropyl-6-flu oro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid and the process for the preparation thereof
EP0787720B1 (en) 1994-10-20 2003-07-16 Wakunaga Seiyaku Kabushiki Kaisha Pyridonecarboxylate derivative or salt thereof and antibacterial containing the same as active ingredient
AU5260096A (en) 1995-01-30 1996-08-21 Wakunaga Seiyaku Kabushiki Kaisha Novel pyridonecarboxylic acid derivatives or salts thereof and antibacterial agent containing the same as active ingredient
US5763454A (en) 1995-06-06 1998-06-09 Pfizer, Inc. Crystal form of anhydrous 7-( 1α,5α,6α!-6-amino-3-azabicyclo 3.1.0!hex-3-yl)-6-fluoro-1-(2,4-difluorophenyl)-1,4-dihydro-4-oxo-1,8 naphthyridine-3-carboxylic acid, methanessulfonic acid salt
US20020032216A1 (en) * 1997-03-21 2002-03-14 Lg Chemical Ltd. Salt of naphthyridine carboxylic acid derivative
KR100286874B1 (ko) * 1998-03-04 2001-04-16 성재갑 보호된 4-아미노메틸-피롤리딘-3-온의 제조방법
GB9820405D0 (en) 1998-09-18 1998-11-11 Smithkline Beecham Plc Process

Also Published As

Publication number Publication date
MA24500A1 (fr) 1998-10-01
SK123699A3 (en) 2000-08-14
JP4781614B2 (ja) 2011-09-28
AP9901649A0 (en) 1999-09-30
BG63972B1 (bg) 2003-08-29
ZA982335B (en) 1999-11-23
DE69814378D1 (de) 2003-06-12
SI0981527T1 (en) 2003-10-31
UA56218C2 (uk) 2003-05-15
PT1179533E (pt) 2004-05-31
HU0600401D0 (en) 2006-07-28
AR012125A1 (es) 2000-09-27
US20150291585A1 (en) 2015-10-15
HUP0600401A3 (en) 2010-05-28
US20170253588A1 (en) 2017-09-07
KR100266499B1 (ko) 2000-12-01
ATE257836T1 (de) 2004-01-15
WO1998042705A1 (en) 1998-10-01
DK1179533T3 (da) 2004-05-03
NZ337748A (en) 2001-03-30
US20090182006A1 (en) 2009-07-16
OA11161A (en) 2003-04-25
EP1179533A3 (en) 2002-03-20
US20160264569A1 (en) 2016-09-15
IS7952A (is) 2005-07-21
DZ2448A1 (fr) 2003-01-11
CA2283671C (en) 2003-09-16
US20080039488A1 (en) 2008-02-14
HU227536B1 (en) 2011-08-29
JP2009051851A (ja) 2009-03-12
US20110312987A1 (en) 2011-12-22
JP3759962B2 (ja) 2006-03-29
NO994595L (no) 1999-09-21
PE67999A1 (es) 1999-09-30
US20140187576A1 (en) 2014-07-03
ES2198697T3 (es) 2004-02-01
US20130065917A1 (en) 2013-03-14
AP1331A (en) 2004-11-26
AU6636698A (en) 1998-10-20
BR9808290A (pt) 2000-05-16
PT981527E (pt) 2003-09-30
ES2213669T3 (es) 2004-09-01
PL191815B1 (pl) 2006-07-31
EP1179533B1 (en) 2004-01-14
IL131812A (en) 2006-04-10
AU726634B2 (en) 2000-11-16
HUP0000728A2 (hu) 2000-09-28
IN188178B (ja) 2002-08-31
NO994595D0 (no) 1999-09-21
JP2004002413A (ja) 2004-01-08
EA199900855A1 (ru) 2000-04-24
CZ288715B6 (cs) 2001-08-15
BG103750A (en) 2000-06-30
DE69821147D1 (de) 2004-02-19
EA001674B1 (ru) 2001-06-25
IS2093B (is) 2006-04-12
DE69821147T2 (de) 2004-11-11
EP1179533A2 (en) 2002-02-13
ATE239724T1 (de) 2003-05-15
US20100240694A1 (en) 2010-09-23
SK284107B6 (sk) 2004-09-08
HUP0000728A3 (en) 2002-12-28
CN1251101A (zh) 2000-04-19
ID22681A (id) 1999-12-09
IS5181A (is) 1999-09-14
CA2283671A1 (en) 1998-10-01
TR199902313T2 (xx) 1999-12-21
HU225412B1 (en) 2006-11-28
DE69814378T2 (de) 2004-02-26
DK0981527T3 (da) 2003-09-01
PL335812A1 (en) 2000-05-22
KR19980080504A (ko) 1998-11-25
NO312515B1 (no) 2002-05-21
IS2095B (is) 2006-04-12
MY137653A (en) 2009-02-27
JP2000510484A (ja) 2000-08-15
EP0981527B1 (en) 2003-05-07
IL131812A0 (en) 2001-03-19
CZ328299A3 (cs) 2000-02-16
SI1179533T1 (en) 2004-04-30
EP0981527A1 (en) 2000-03-01
CN1131229C (zh) 2003-12-17
CZ288673B6 (cs) 2001-08-15
SA98181055B1 (ar) 2006-10-11
US7700617B2 (en) 2010-04-20

Similar Documents

Publication Publication Date Title
HK1026698A1 (en) Salt of naphthyridine carboxylic acid derivative
NZ333168A (en) Process for preparing 6,7,8,9-tetrahydro-1h-imidazo[4,5-c]quinolin-4-amine derivatives
HUP0202494A2 (en) Imidazo[1,2-a]pyridine and pyrazolo[2,3-a]pyridine derivatives, process for their preparation and pharmaceutical compositions containing them
HUP0000450A2 (hu) 7-(2-Oxa-5,8-diazabiciklo[4.3.0]non-8-il)-kinolon-karbonsav és -naftiridon-karbonsav-származékok alkalmazása Helicobacter pylori fertőzések, és az ezzel kapcsolatos gyomor-bél megbetegedések gyógyítására szolgáló gyógyszerkészítmények előállítására
PL366858A1 (en) Use of substituted imidazo[1,2-a]-pyridine compounds as medicaments
HUP0004704A3 (en) Dihydrofuro [3,4-b] quinolin-1-one derivatives, process for their preparation and pharmaceutical compositions containing them
AU617974B2 (en) (s)-7-(3-amino-1-pyrrolidinyl)-1-cyclopropyl-6-fluoro-1, 4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid
WO2001017961A3 (en) Intermediates for the production of naphthyridine-3-carboxylic acid derivatives
HUP0300569A3 (en) Pyrano[2,3-c]imidazo[-1,2-a]pyridine derivatives for the treatment of gastrointestinal disorders and pharmaceutical compositions containing the compounds
CZ20011857A3 (cs) Krystalická modifikace B kyseliny 8-kyano-1-cyklopropyl-7-(1S,6S-2,8-diazabicyklo-[4,3,0]nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chinolinkarboxylové, způsob přípravy a její použití ve farmaceutických přípravcích
HUP0003394A3 (en) Pyrido[2,3-b][1,5]benzodiazepine derivatives, their use, process for their preparation and pharmaceutical compositions containing them
HUP0200006A2 (en) Crystal modification c of 8-cyano-1-cyclopropyl-7- (1s, 6s-2,8-diazabicyclo - [4.3.0]nonan-8-yl)-6-fluoro-1,4-dihydro-4-oxo-3-quinoline carboxylic acid process for their preparation, pharmaceutical composition comprising thereof and their use
HUP0104367A3 (en) Semi-hydrochloride of 8-cyan-1-cyclopropyl-7-(1s,6s-2,8-diazabicyclo[4.3.0]nonan-8-yl)-6-fluoro-1,4-dihydro-4-oxo-3-quinoline carboxylic acid, process for its preparation and pharmaceutical composition thereof
HUP0200053A3 (en) Crystal modification d of 8-cyano-1-cyclopropyl-7-(1s,6s-2,8-diazabicyclo-[4.3.0]nonan-8-yl)-6-fluoro-1,4-dihydro-4-oxo-3-quinoline carboxylic acid, process for its preparation and pharmaceutical compositions containing the same
IS3938A (is) Aðferð við framleiðslu nýrra pyrimídó [1',6':1,2]pyridó [3,4-b] indól afleiða og lyfjablandna sem innihalda þær

Legal Events

Date Code Title Description
PF Patent in force
PE Patent expired

Effective date: 20180319